Sooner Clinical Research | Oklahoma City, OK

Research site

(Unclaimed)

Location

5929 N. May Avenue, Suite 401, Oklahoma City, Oklahoma, United States of America

Site insights

Top conditions

Top treatments

Cariprazine

Rapastinel

Pregabalin

SPD489

Dapagliflozin

Balsalazide Disodium

Eslicarbazepine Acetate

BI 1569912

Lyrica

ABBV-932

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 61 total trials

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Active, not recruiting

Depressive Disorder, Major

Drug: Aticaprant

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. (3112 Ped BPD)

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling

Bipolar I Disorder

Depression

Drug: Placebo

Drug: Cariprazine

A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \&...

Active, not recruiting

Major Depressive Disorder

Other: Placebo

Drug: SEP-363856

GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The mai...

Enrolling

Major Depressive Disorder

Drug: Zelquistinel

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO)

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how saf...

Enrolling

Bipolar II Disorder

Bipolar I Disorder

Drug: Placebo for ABBV-932

Drug: ABBV-932

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately t...

Enrolling

Generalized Anxiety Disorder (GAD)

Drug: Antidepressant Therapy (ADT)

Drug: ABBV-932

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive...

Enrolling

Major Depressive Disorder (MDD)

Drug: Ropanicant

Drug: Placebo